CLPT 8-K SEC Filing Analysis

Latest settled — T+5d

CLPT ▼ -8.38% at T+5d

NEUTRAL call ✗ call lost -8.38% · α vs SPY -7.66% · entry $12.77 → $11.70

Next anchor: T+20d tomorrow

Last close $13.38 (close Jun 8) · +4.78% from $12.77 entry

Entry anchored
May 13, 03:59 PM ET
via Databento tick

T+1d

0.00%

call 0.00% · α -0.01%

$12.77

settled 27d ago

T+5d

-8.38%

call -8.38% · α -7.66%

$11.70

settled 21d ago

T+20d

—

call — · α —

—

tomorrow

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

ClearPoint Neuro reported Q1 2026 revenue of $12.1M (+43% YoY), beating pre-release consensus? (no explicit consensus but beat prior year), but EPS of -$0.32 missed the Street consensus of -$0.28. Gross margin expanded to 64%, but operating expenses grew 44% and net loss widened to $9.6M. Guidance for full-year 2026 revenue of $52-56M was maintained.

Key Financial Metrics

Guidance

$52.0 million and $56.0 million

maintained

Free Cash Flow

-$8.6M

Gross Margin

64%

Actionable Insight

Strong top-line growth and margin expansion are positives, but widening losses and cash burn persist. Guidance unchanged suggests management is confident in H2 improvements from IRRAS synergies. Monitor cash runway and next quarter's op. leverage progress; any sign of cash burn acceleration would be concerning.

Key Facts

Q1 2026 revenue $12.1M, +43% YoY (16% organic), record quarter
GAAP EPS -$0.32 vs consensus -$0.28 (miss of 14.3%)
Gross margin 64%, up from 60% in Q1 2025
Operating expenses $16.2M, +44% YoY, driven by IRRAS integration and headcount
Net loss $9.6M vs $6.0M in Q1 2025
Cash and equivalents $35.6M at March 31, 2026 (down from $45.9M at Dec 31, 2025)
Full-year 2026 revenue guidance maintained at $52-56M
Company expects cost synergies from IRRAS to reduce cash burn in H2 2026 and targets cash neutrality by 2027

Financial Impact

Revenue beat prior year by $3.6M, but net loss increased by $3.5M; EPS miss by $0.04 vs consensus

revenueepsgross marginoperating expensescash flow

Risk Factors

Integration of IRRAS may not deliver expected cost synergies on time
Cash burn could accelerate if revenue growth slows or expenses continue to outpace revenue
Dependence on biopharma partner programs and clinical trial progress for future revenue

Market Snapshot

Exchange

Nasdaq

Sector

Surgical & Medical Instruments & Apparatus

Analyst Consensus

88% bullish (8 analysts)

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001193125-26-221596
Document: clpt-20260513.htm	0001193125-26-221596
Document: clpt-ex99_2.htm	0001193125-26-221596
Document: 0001193125-26-221596-index-headers.html	0001193125-26-221596
Document: 0001193125-26-221596-index.html	0001193125-26-221596
Document: 0001193125-26-221596.txt	0001193125-26-221596
8-K Data (Synthetic)	0001193125-26-221596

3 reports for CLPT

T+1T+5T+20T+60

Filters

Reports for CLPT — sortable, filterable
	Type				Now
May 21, 2026 19d ago	8-K NEUTRAL ★ 3/10	$11.44 $12.64	▲ +10.49%	▲ +8.83%	$13.38 (+16.96%)
May 20, 2026 20d ago	144 NEUTRAL ★ 2/10	$11.70 $12.67	▲ +8.29%	▲ +6.44%	$13.38 (+14.36%)
May 13, 2026 27d ago	8-K MIXED ★ 5/10	$12.77 $11.70	▼ −8.38%	▼ −7.66%	$13.38 (+4.78%)

US Market Status

Market Closed — Opens in 6h 56m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access